Amplia Therapeutics Limited (INNMF)
USD 0.04
(-15.61%)
USD 0.04
(-15.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 3.42 Million AUD | 20.29% |
| 2023 | 2.84 Million AUD | 8.07% |
| 2022 | 2.63 Million AUD | 388.95% |
| 2021 | 539.13 Thousand AUD | 5.58% |
| 2020 | 510.62 Thousand AUD | -3.08% |
| 2019 | 526.85 Thousand AUD | 88.55% |
| 2018 | 279.42 Thousand AUD | -69.22% |
| 2017 | 907.87 Thousand AUD | -11.97% |
| 2016 | 1.03 Million AUD | 127.72% |
| 2015 | 452.89 Thousand AUD | 12.18% |
| 2014 | 403.73 Thousand AUD | 111.38% |
| 2013 | 191 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.8 Million AUD | -1.48% |
| 2024 Q2 | 2.8 Million AUD | 0.0% |
| 2024 Q4 | 3.42 Million AUD | 0.0% |
| 2024 FY | 3.42 Million AUD | 20.29% |
| 2023 Q3 | 2.84 Million AUD | 1.8% |
| 2023 Q1 | 2.79 Million AUD | 6.16% |
| 2023 FY | 2.84 Million AUD | 8.07% |
| 2023 Q2 | 2.79 Million AUD | 0.0% |
| 2023 Q4 | 2.84 Million AUD | 0.0% |
| 2022 Q4 | 2.63 Million AUD | 0.0% |
| 2022 Q2 | 336.42 Thousand AUD | 0.0% |
| 2022 FY | 2.63 Million AUD | 388.95% |
| 2021 Q4 | 538 Thousand AUD | 0.0% |
| 2021 FY | 539.13 Thousand AUD | 5.58% |
| 2021 Q2 | 615.55 Thousand AUD | 0.0% |
| 2020 Q2 | 218.19 Thousand AUD | 0.0% |
| 2020 Q4 | 510.62 Thousand AUD | 0.0% |
| 2020 FY | 510.62 Thousand AUD | -3.08% |
| 2019 FY | 526.85 Thousand AUD | 88.55% |
| 2019 Q4 | 526.85 Thousand AUD | 0.0% |
| 2018 Q4 | 279.42 Thousand AUD | 0.0% |
| 2018 FY | 279.42 Thousand AUD | -69.22% |
| 2017 Q4 | 907.87 Thousand AUD | 0.0% |
| 2017 FY | 907.87 Thousand AUD | -11.97% |
| 2016 FY | 1.03 Million AUD | 127.72% |
| 2016 Q4 | 1.03 Million AUD | 0.0% |
| 2015 FY | 452.89 Thousand AUD | 12.18% |
| 2015 Q4 | 452.89 Thousand AUD | 0.0% |
| 2014 FY | 403.73 Thousand AUD | 111.38% |
| 2013 FY | 191 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 93.182% |
| Skye Bioscience, Inc. | 14.07 Million USD | 75.648% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 94.193% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -323.692% |
| Qrons Inc. | 1.48 Million USD | -130.185% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 78.454% |
| CSL Limited | 18.62 Billion USD | 99.982% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.271% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 63.799% |
| Regen BioPharma, Inc. | 5.45 Million USD | 37.211% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.426% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7566.903% |
| Rebus Holdings, Inc. | 5.24 Million USD | 34.628% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -12391.521% |
| Neon Bloom, Inc. | 1.22 Million USD | -179.462% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1603.892% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.571% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 64.237% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -712.87% |
| SQZ Biotechnologies Company | 50.03 Million USD | 93.152% |
| Intellipharmaceutics International Inc. | 12 Million USD | 71.464% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 11.025% |
| Mesoblast Limited | 188.44 Million USD | 98.182% |
| Marizyme, Inc. | 26.67 Million USD | 87.154% |
| Genus plc | 485 Million USD | 99.293% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 41.348% |
| Pharming Group N.V. | 244.07 Million USD | 98.596% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -70.476% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -36.183% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 9.821% |
| ContraFect Corporation | 32.53 Million USD | 89.466% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -72.956% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 10.472% |
| IMV Inc. | 37.93 Million USD | 90.966% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 70.906% |
| MultiCell Technologies, Inc. | 1617.67 USD | -211735.479% |
| ONE Bio Corp. | 27.49 Million USD | 87.537% |
| Accustem Sciences Inc. | 1.07 Million USD | -217.52% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.574% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -62.018% |
| Q BioMed Inc. | 8.13 Million USD | 57.865% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.868% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 33.409% |
| Biomind Labs Inc. | 1.49 Million USD | -128.665% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.114% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 62.102% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 81.38% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -138.991% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2311.625% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 40.36% |
| GB Sciences, Inc. | 5.41 Million USD | 36.746% |
| Alpha Cognition Inc. | 7.16 Million USD | 52.172% |
| HST Global, Inc. | 593.59 Thousand USD | -477.298% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -172.142% |
| Halberd Corporation | 728.71 Thousand USD | -370.25% |
| Enzolytics Inc. | 365.26 Million USD | 99.062% |
| Agentix Corp. | 2.51 Million USD | -36.496% |
| Resverlogix Corp. | 67.39 Million USD | 94.915% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -308.569% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.23% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -99.93% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 86.152% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 71.211% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 6.504% |
| AVAX Technologies, Inc. | 3.99 Million USD | 14.196% |
| Zenith Capital Corp. | 27.56 Thousand USD | -12329.9% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.742% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1335.886% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 8.235% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -403.324% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -26.374% |
| Kadimastem Ltd | 3.5 Million USD | 2.227% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5020.051% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -637.423% |
| LadRx Corporation | 2.2 Million USD | -55.726% |
| Cell Source, Inc. | 15.8 Million USD | 78.321% |
| Regen BioPharma, Inc. | 5.45 Million USD | 37.211% |
| NovAccess Global Inc. | 7.86 Million USD | 56.406% |
| Affymax, Inc. | 8.87 Million USD | 61.371% |
| Itoco Inc. | 1.65 Million USD | -107.289% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -67.033% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 43.349% |
| Mobile Lads Corp. | 1.31 Million USD | -160.891% |
| CytoDyn Inc. | 127.89 Million USD | 97.321% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8098.28% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -118.772% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 68.975% |
| SYBLEU INC | 681.41 Thousand USD | -402.896% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 43.841% |
| International Stem Cell Corporation | 5.27 Million USD | 35.062% |
| Bioxytran, Inc. | 3.24 Million USD | -5.456% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -447.579% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 25.781% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.641% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 84.609% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -69.192% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 37.444% |
| Neutra Corp. | 973.52 Thousand USD | -251.998% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 88.19% |
| PureTech Health plc | 125.58 Million USD | 97.271% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 8.792% |
| IXICO plc | 1.9 Million USD | -80.33% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 83.308% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.683% |
| CSL Limited | 18.62 Billion USD | 99.982% |
| Cellectis S.A. | 249.36 Million USD | 98.626% |